The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress

Copenhagen, Denmark, 3 October 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to inform of presentation of the outstanding clinical data from the completed phase I/IIa trial with FG001 in patients with aggressive brain cancer undergoing surgery, at the World Molecular Imaging Congress (WMIC) held 28 September – 1 October 2022 in Miami, US. Promising pre-clinical data on FG002 was also presented at the same conference.

The release as fetched from its publisher. fluoguide.com ↗